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Kidney and Liver Disease patients
with liver volume ≥ 2000mL
Lanreotide 120 mg 
sc every 28 days
A 120-week randomized clinical trial
Primary outcome
% change in height adjusted total
liver volume (hTLV) from baseline 
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Background and aims 
Polycystic liver disease is the most common extra-renal manifestation of autosomal dominant 
polycystic kidney disease (ADPKD). There is need for robust long-term evidence for the volume-
reducing effect of somatostatin analogues. We made use of data from an open-label, randomized 
trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined 
height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD. 
Methods 
We performed a 120-week study comparing the reno-protective effects of lanreotide vs standard 
care in 305 patients with ADPKD (the DIPAK-1 study). For this analysis we studied the 175 patients 
with polycystic liver disease, with hepatic cysts identified by magnetic resonance imaging and liver 
volume ≥2000 ml. Of these, 93 patients were assigned to a group that received lanreotide (120 mg 
subcutaneously every 4 weeks) and 82 to a group that received standard care (blood pressure 
coKN2ntrol, a sodium-restricted diet, and anti-hypertensive agents). The primary endpoint was 
percentage change in hTLV between baseline and end of treatment (week 120). A secondary 
endpoint was change in hTLKV. 
Results 
At 120 weeks, hTLV decreased by 1.99% in the lanreotide group (95% CI, –4.21 to 0.24) and increased 
by 3.92% in the control group (95% CI, 1.56–6.28). Compared to controls, lanreotide reduced the 
growth of hTLV by 5.91% (95% CI, –9.18 to –2.63; P<.001). Growth of hTLV was still reduced by 3.87% 
at 4 months after the last injection of lanreotide compared to baseline (95% CI, –7.55 to –0.18; 
P=.04). Lanreotide reduced growth of hTLKV by 7.18% compared with controls (95% CI, –10.25 to –
4.12; P<.001). 
Conclusion 
In this subanalysis of a randomized trial of patients with polycystic liver disease due to ADPKD, 













effect was still present 4 months after the last injection of lanreotide. ClinicalTrials.gov no: 
NCT01616927 
Keywords: Polycystic liver disease; somatostatin analogues; liver size; drug 
INTRODUCTION 
Polycystic liver disease (PLD) is the most common extra-renal manifestation of autosomal dominant 
polycystic kidney disease (ADPKD).
1
 The overall prevalence of hepatic cysts in ADPKD is 83%, and 
increases to more than 90% of patients older than 40-years-of-age.
2
 While the majority of PLD 
patients will remain asymptomatic, some patients develop hepatomegaly leading to abdominal pain, 
early satiety, shortness of breath, poor nutritional status and decreased quality of life (QoL).
3, 4
 




 Experimental data suggest that somatostatin analogues possess a liver volume reducing 
effect by inhibiting cAMP production and as a consequence, cell proliferation and fluid secretion. In a 
pooled analysis of three randomized controlled trials (RCTs), lanreotide or octreotide (both long-
acting somatostatin analogues) reduced liver volume with an average of 3.6% and improved health 
related quality of life in 6-12 months 
6-9
, but it is unclear whether the benefits extend beyond 12 
months. A number of uncontrolled open label studies 
10-12
 and a post-hoc analysis of a RCT 
13
 
suggested that prolonged somatostatin analogue treatment may be effective to reduce liver volume, 
but that discontinuation of therapy leads to re-growth. The uncontrolled nature of these studies, the 
limited number of included patients and their relatively small liver volume did not allow firm 
conclusions with respect to the liver volume reducing effect of these drugs. There is therefore a need 
for robust evidence of long-term somatostatin analogue administration in PLD, especially in those 
with hepatomegaly. We hypothesized that a liver volume reducing effect can be achieved after 120 














 In the DIPAK-1 study (an investigator driven, open-label randomized clinical, multicenter 
trial), 305 later stage ADPKD patients were randomized to lanreotide treatment for 120 weeks or 
standard care to evaluate renoprotective potential.
14
 Although lanreotide treatment did not preserve 
kidney function, data suggested a beneficial effect on the rate of total kidney volume (TKV) growth. 
For this report we assessed the long-term effect of lanreotide on height adjusted liver volume (hTLV) 
as well as on combined height adjusted liver and kidney volume (hTLKV) in PLD patients.  
 
METHODS 
Study design and participants 
This study is a predefined sub-analysis of the DIPAK-1 study with focus on liver-related endpoints. A 
description of the design, outcome measures and rationale of the DIPAK-1 study, ‘a randomized 
controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal 
dominant polycystic kidney disease’, has been published previously.
15
 The DIPAK-1 study included 
subjects aged 18-60 years, who had ADPKD based on the modified Ravine criteria 
16
 and an estimated 




 For the present study, we selected 
ADPKD patients with PLD and hepatomegaly, a priori defined in the study protocol as a liver volume 




In the DIPAK-1 study, after a screening and baseline evaluation, eligible patients were stratified by 
sex, age (≤ or > 45 years) and eGFR (≤ or > 45 ml/min/1.73m
2
). Patients were randomly assigned (1:1) 
with a block size of 6 to either lanreotide on top of standard care or to the control group that 




Standard care was defined as blood pressure control (<140/90 mmHg), if needed by treatment with a 













subcutaneously (SC) every 4 weeks. Dosage was down-titrated to 90 mg SC every 4 weeks in case 
eGFR levels dropped below 30 ml/min. In patients who experienced significant side effects dosage was 
step-by-step down-titrated to 90 mg, 60 mg or stopped. Lanreotide was injected by trained nurses via 




After the baseline visit, patients were seen at one of the four study centers (Groningen, Leiden, 
Nijmegen and Rotterdam) at weeks 4, 8, 12, 48, 96, 120 and at week 132. After week 120 (End of 
Treatment) treatment with lanreotide was discontinued and patients were seen again 12 weeks later 
at a post-treatment visit (week 132). In case patients dropped out before week 120, an early end of 
treatment and early post-treatment visit were performed. Blood samples for safety assessment were 
obtained every study visit. At baseline, end of treatment (or early end of treatment) and post-
treatment visits, standardized MRI scans were obtained without use of contrast agent.
17
 Total liver 
volume (TLV) and total kidney volume (TKV) were assessed with manual tracing planimetry by trained 
reviewers blinded for patient identity, treatment allocation and order of study visit.
15
 TLV and TKV 
were adjusted for height (hTLV) by dividing TLV or TKV by length (in meters) of the patient.
14
 
Combined height adjusted liver and kidney volume (hTLKV) was assessed as hTLV + hTKV. 
 Health related quality of life (HR-QoL) was measured using the gastrointestinal symptoms 
questionnaire.
18
 The 11 items were partially derived from the Gastrointestinal Symptom Score 
19
 and 
modified with symptoms that are characteristic for symptomatic PLD based on expert opinion, and 
include: lower and upper abdominal pain, heartburn, regurgitation, nausea, vomiting, loss of 
appetite, early satiety, dyspnea, increase of abdominal waist and involuntary weight loss. All 
symptoms were assessed using a 7-point Likert scale, ranging from 1 (“none”) to 7 (“very severe”). 

















Primary outcome was change in hTLV from baseline to end of treatment (week 120), calculated as 
percentage difference. Main secondary outcomes were: I) absolute change in TLV and hTLV between 
baseline and end of treatment (week 120), II) absolute change in TLV and hTLV, and proportional 
change in hTLV between baseline and post-treatment visit (week 132), III) absolute change in TLKV 
and hTLKV, and proportional change in hTLKV between baseline and end of treatment (week 120) as 
well as between baseline and post-treatment visit (week 132). Other secondary outcomes were 
change in symptom severity score and (serious) adverse events. 
Ethical Considerations 
This trial is registered with ClinicalTrials.gov (number NCT01616927). All patients provided written 
informed consent.
14
 Ethical considerations are outlined in the study protocol.
15
 All authors had access 
to the study data, and reviewed and approved the final manuscript. 
Statistical analysis 
Clinical outcome variables were analyzed with an intention-to-treat approach, for all patients for 
whom baseline and end of treatment MRI were available. Variables were expressed as mean (95% 
confidence interval [CI]) or median (interquartile range [IQR]). Differences in baseline characteristics 
were tested with independent t-tests for normally distributed data or Mann-Whitney U test for 
skewed data. Randomization did not include stratification for baseline volume, therefore our primary 
and main secondary endpoints were evaluated using an ANCOVA model with adjustment for baseline 
volume corresponding with the outcome to be analyzed. Data are presented as estimated marginal 
means (95% CI). Treatment effect was defined as difference in effect between the somatostatin 
analogue group and control group. A Spearman’s rank order correlation was computed to assess the 
relationship between change in hTLV and hTKV.  
 A priori defined subgroup analyses were performed using ANCOVA with the primary or 
secondary endpoint as dependent variable, and as independent variables treatment group (yes/no), 













and an interaction term of treatment group times subgroup to investigate possible effect 
modification. 
   The number of included males in previous studies was low (9 patients or less) which limits 
the evidence for effect in this subgroup.
7-9, 13
 In this trial we expected a considerably larger number of 
male subjects to be included. We therefore analyzed the difference in treatment effect on hTLV and 
hTLKV in males and females separately, regardless whether gender was identified as a moderator for 
effect. 
  Genetic assessment showed that one patient was carrier of an extremely rare combined 
pathogenic truncating mutations in the PKD1 as well as in the PKD2 gene. This patient, who received 
lanreotide, had an extreme increase in TKV of 154% after 132 weeks (specific details of this patient 
have been published previously).
14
 Therefore we performed sensitivity analyses after removal of this 
outlier.  
  Analyses for symptom severity score were performed using ANCOVA models after adjusting 
for baseline score. All patients were included for safety analyses, all (serious) adverse events were 
reported. Statistical analyses were performed with SPSS Statistics version 22 and all calculated P 




The original DIPAK-1 study included 305 patients.
14
 A total of 175 patients (80 males and 95 females) 
met our criteria (TLV ≥2000 ml) and were eligible for inclusion in the present analysis. A flowchart of 
the population of this study is shown in figure 1. A total of 93 patients received lanreotide while 82 
were assigned to the control group. Baseline hTLV was higher in patients on lanreotide compared to 
controls (1528 ml/m [IQR 1250 – 2443] vs. 1376 [IQR 1219 – 1687]; p =0.04), as was hTLKV (3006 
ml/m [IQR 2460 – 4110] vs. 2694 [2183 – 3683]; p=0.04). Other baseline characteristics were not 













least two MRI scans, at baseline visit and end of treatment (or early end of treatment), and were 
therefore eligible for our primary efficacy analysis (table S1). Figure 1 shows the reasons for loss to 
follow-up. We analyzed differences in baseline characteristics between patients who were lost to 
follow-up. In both groups, predominantly patients with relative high liver volume dropped out of the 
study (table S2 and S3), but there was no difference in characteristics of patients that were lost to 
follow-up in the two study groups.  
Primary outcome 
Between baseline and end of treatment, lanreotide decreased hTLV by 1.99%, while hTLV increased 
with 3.92% in controls (table 2 and figure 2A). Overall, the advantage of lanreotide over control was -
5.91% (95% CI -9.18 to -2.63; p<0.001). The difference in annualized percentage change in hTLV with 
lanreotide versus control was -3.37% (95% CI -5.56 to -1.19; p=0.003) (table S4). Absolute treatment 
effect between the groups was 140 ml in TLV (95% CI -263 to -18; p=0.03) and 79 ml/m in hTLV (95% 
CI -150 to -7; p=0.03) (table 2). Individual patient analysis showed that the proportion of patients 
with a decrease in liver volume was 60.2% in the lanreotide group compared to 31.1% in the control 
group (p <0.001) (figure 2B).  
Secondary outcomes 
We evaluated the effect on hTLV four months after cessation of lanreotide. Difference between the 
two groups remained significant with a beneficial effect of -3.87% (95% CI -7.55 to -0.18; p=0.04) in 
favor of lanreotide (table 2). Overall difference in absolute change in TLV was -87 ml, (95% CI -237 to 
63; p=0.25). Pre-specified subgroup analyses revealed no subgroup that benefited differently from 
lanreotide between baseline and end of treatment, and between baseline and post-treatment (figure 
2C; figure S1). 
Next, we assessed volume change of combined polycystic liver and kidneys between baseline and 
end of treatment. hTLKV increased in the lanreotide group with 2.21% and in the control group with 













lanreotide (table 3). The difference in annualized percentage change in hTLKV with lanreotide versus 
control was -3.70% (95% CI -5.74 to -1.67; p<0.001) (table S4). Difference in absolute volume change 
in the lanreotide group compared to the control group was for TLKV 353 ml (95% CI -554 to -152; 
p=0.001) and for hTLKV 192 ml/m (95% CI -306 to -77; p=0.001) (table 3). Again, the proportion of 
patients who had a decrease in hTLKV was higher in the lanreotide group (37.3%) than in the control 
group (14.8%; p<0.001). We performed similar pre-specified subgroup analyses for this secondary 
endpoint. No subgroup significantly moderated the effect on combined hTLKV from baseline to end 
of treatment (figure S2). In line with the results of the complete DIPAK-1 population, lanreotide 
significantly attenuated absolute and percentage growth in total kidney volume (table S5). We 
assessed the correlation between growth in hTLV and hTKV and found a positive correlation in the 
whole population (rs = 0.33, p<0.001). This correlation was significant in lanreotide treated patients 
(rs = 0.26, p=0.02) but not in controls (rs = 0.20, p=0.09).  
A significant volume reducing effect of lanreotide on hTLKV was still present 4 months after cessation 
of lanreotide. At the post-treatment visit, patients in the lanreotide group had a 5.43% (95% CI -9.13 
to -1.74; p=0.004) less increase in hTLKV compared to the control group (table 3). Absolute 
treatment effect on TLKV was 256 ml (95% CI -515 to 4; p=0.05). 
To determine whether lanreotide treatment has an effect on symptoms, we assessed change in 
symptom severity score. Baseline symptom severity score was 9.1 (IQR 3.0 to 18.6) in the lanreotide 
group (n=93) and 6.1 (IQR 1.5 to 15.5; p=0.1) in the control group (n=81). After correction for 
baseline score, symptom severity score increased with 2.7 (95% CI 0.7 to 4.7) in lanreotide treated 
patients and with 2.6 (95% CI 0.5 to 4.7) in controls. There was no difference in change in symptom 
severity score between the groups (p=0.9). Median symptom severity score at baseline was added to 
our subgroup analyses and showed that it was no moderator for effect on our primary outcome 
change in hTLV (p=0.7) nor for effect on symptom severity score (p=0.94). 













A priori we defined to investigate the effect of lanreotide in both sexes separately. At baseline there 
were gender specific differences in liver and kidney volume. hTLV was significantly higher in females 
(1654 ml/m vs. 1283 ml/m; p<0.001) while hTKV was higher in males (1339 ml/m vs. 883 ml/m; 
p<0.001). Combined, baseline hTLKV was not different between males and females (p=0.5). After 120 
weeks, liver growth in the control group was similar in males and females. However, only in females 
a significant treatment effect of lanreotide compared to controls was found (-7.68%, p=0.001). In 
males, the treatment effect of -4.05% did not reach clinical significance (p=0.09) (figure 3A).  
The control group demonstrated that combined liver- and kidney volume growth was larger in males 
(p<0.01) compared to females, which can be fully attributed to the fast growth of kidney volume in 
males. If measured from baseline to end of treatment, the hTLKV treatment effect of lanreotide 
versus control group was significant in males (-6.59%, p=0.002) as well as females (-7.48%, p<0.001) 
(figure 3B). In general, subgroup analysis revealed that gender was not an effect modifier for change 
in hTLV (p=0.3) and hTLKV (p=0.8).  
Several post-hoc analyses were performed. The observation period between baseline and end of 
treatment was shorter in the lanreotide group (2.06 ± 0.54 years) compared to controls (2.31 ± 0.06 
years; p=<0.001). We therefore examined whether the observed difference affected our primary 
outcome. Addition of the variable ‘duration observation period’ to our ANCOVA model excluded any 
effect on our results (between subjects effect: p=0.9).  
As described in the original DIPAK-1 trial publication, one extreme outlier in the lanreotide group had 
a very rare combination of truncating mutations in both the PKD1 and PKD2 gene, most likely leading 
to very rapid increase of liver- and kidney volume.
14
 A sensitivity analysis after removal of this 
extreme outlier further strengthened our findings (table S6). For example, absolute treatment effect 
in TLKV was now significantly in favor of lanreotide with a total difference of 364 ml (95% CI -560 to -















Lanreotide was down-titrated in 23 patients (to 90mg, subcutaneously, once every 4 weeks in 20 
patients and to 60mg, subcutaneously, once every 4 weeks in three patients). In 8 patients, this 
titration was done per protocol because patients reached an eGFR less than 30mL/min/1.73 m2. In 
15 patients down-titration was done because of adverse events (7x gastrointestinal complaints, 3x 
fatigue/malaise, 2x bradycardia, 1x hypoglycemia, 1x hair loss and 1x liver cyst infection). Of these, 6 
patients stopped lanreotide because of persistent complaints despite down-titration and 2 because 
of other reasons (nephrectomy and loss of confidence in the drug). In 6 out of 7 patients in which 
down-titration was done because of gastrointestinal symptoms, side effects were tolerable with 
lower dose. A total of 18 patients (19%) stopped lanreotide at once, of whom 14 did so because of 
adverse events (4x fatigue/malaise, 2x renal cyst bleeding, 6x liver cyst infection, 2x gastrointestinal 
symptoms). Of note, patients who discontinued lanreotide underwent an early MRI and were 
included in our analysis. 
We assessed all (serious) adverse events (SAEs) in this population. SAEs occurred in 38 patients of 
which 28 (30.1%) in the lanreotide group and 10 (12.2%) in the control group (table S7). Aside from 
hepatic cyst infections, which have been described previously 
20
, there were no significant 
differences between SAE occurrence (at least possibly related to lanreotide) in both groups. A total of 
14 SAEs (including 7 episodes of hepatic cyst infections) in the lanreotide group were at least possibly 
related to the drug. The proportional numbers of AEs in this subgroup are similar to the numbers of 






This study demonstrates that 120 weeks treatment with lanreotide in ADPKD patients with large 













beneficial effect is still present four months after cessation of treatment. Lanreotide not only reduces 
liver volume by 5.9%, but also attenuates growth in kidney volume, resulting in a 7.2% reduction of 
combined liver- and kidney volume compared to standard of care.  
 The liver volume reducing effect of somatostatin analogues has been subject of several trials, 
mostly small and with a short follow-up, but a recent single center study had a longer duration of 
follow-up. That study evaluated 27 ADPKD patients and exposed them during 3 years to octreotide-
LAR (40 mg monthly) or placebo. Liver volume decreased with octreotide and increased with placebo 
resulting in a net difference of -13.9% in favor of octreotide. The reductions in liver volume were 
maintained for 2 years after treatment ended.
13
 In this trial most patients did not have hepatomegaly 
(median TLV ~1500-1600) and would have been excluded from our study which hampers direct 
comparison with the present results. 
In the present trial, 120 weeks of lanreotide treatment resulted in a 5.9% lower hTLV growth 
rate compared to 4.5% in a trial with a duration of 6 months 
7
 or 5.9% in a trial of 12 months 
8
 (table 
S8). This may suggest an absence of a linear relationship between treatment duration and treatment 
effect. It has been hypothesized that the expression of somatostatin receptors is down-regulated 
during prolonged treatment with somatostatin analogues.
21-23
 SSTR down-regulation may explain 
why overall treatment effect is not linear to treatment duration. Several other factors, however, may 
also explain this finding. First, the DIPAK-1 trial has a large sample size including a large proportion of 
males, a broad spectrum of PLD severity and later stage ADPKD patients (table S8). It is known that 
young females respond better to somatostatin analogue treatment, and these were overrepresented 
in other trials.
6
 Second, some of the previous studies were performed with lanreotide 
7
 and others 
with octreotide.
8, 9, 13
 Studies have suggested differences in receptor affinity between the various 
somatostatin analogues.
24
 These two considerations make it clear that differences in patient 
characteristics, and differences in somatostatin analogues tested, do not allow a direct comparison 













Literature has shown that somatostatin analogues have an acute repressive effect on TLV 
that is reversible after stopping (short-term) treatment.
11
 This trial documents that the beneficial 
effects of 120 week treatment with lanreotide are seen immediate after stopping the drug but also 
persist throughout the washout period until at least 4 months after the last lanreotide injection. The 
half-life of prolonged-release lanreotide (90 mg) is 25.5 days, suggesting that exposure to lanreotide 
at 4 months would be well below target levels.
25
 In addition, another trial suggested that the effect 
of somatostatin analogues on TLV persist even two years after cessation of treatment.
13
 These 
observations suggest that with 120 weeks of lanreotide not only an acute, reversible, possibly 
hemodynamic effect is obtained, but also a chronic, non-reversible, probably structural beneficial 
effect. Future studies will have to establish whether there is a linear relationship between treatment 
duration and this chronic effect of somatostatin analogues on TLV and TKLV.  
 An important finding in this study is that 120 weeks of lanreotide treatment decreased 
combined liver- and kidney volume growth by 353 ml in ADPKD patients which is a clinical relevant 
reduction.
26
 Although liver and kidney volume are surrogate markers for disease severity in ADPKD, 
previous studies have shown that somatostatin analogues improve health related quality of life in 
symptomatic PLD.
26
 Larger liver volumes are associated with symptomatic disease and lower QoL
27
 
and severity of hepatomegaly is associated with a 6-fold higher risk for pressure-related 
complications.
28
 An analysis of baseline data of the DIPAK-1 study showed that both hTLV and even 
more strongly hTLKV were significantly associated with pain and gastrointestinal symptoms.
18
 These 
studies emphasize the need to prevent further liver- and kidney growth in ADPKD. 
There is a phenotypic gender difference in ADPKD. Males have earlier need for renal 
replacement therapy and higher rates of kidney cyst expansion, but are less prone to develop 
polycystic livers than females do.
29
 This is reflected by our finding that 80% of the male ADPKD 
patients in our trial had mild PLD (hTLV <1600 ml/m) compared to 46% of females. In this study, liver 
growth was suppressed in males on lanreotide compared to controls, albeit not to a significant level. 













subpopulation. The fact that we did not find effect modification by gender suggests that men too 
benefit from lanreotide. 
 
Limitations 
This study comes with several limitations. First, randomization in the original DIPAK-1 trial did not 
include stratification for baseline liver volume, which led to an imbalance in group distribution of 
hTLV and hTLKV. Lanreotide treated patients had higher liver volume at baseline, but similar age. 
Consequently, the subjects in the lanreotide group are likely to have faster liver disease progression, 
which can have led to an underestimation the true treatment effect of lanreotide. We adjusted all 
our analyses for baseline TLV to overcome this limitation. Second, the DIPAK-1 trial was not designed 
to show the effect of lanreotide on symptoms in PLD. On the basis of the assessment of patients at 
time of visits during this clinical trial we can state that the proportion of symptomatic PLD patients 
was low. Indeed, using the symptom severity score, most patients had a low score and did not show 
a benefit with lanreotide compared to control treatment. However, the symptom severity score that 
we used is not a validated patient reported outcome measure and may not be sensitive enough to 
detect change in symptoms. Only recently, a polycystic liver disease specific questionnaire (PLD-Q) 
was developed and validated to assess symptoms in PLD 
30
, but this questionnaire was not available 
at time of the study design. Although the patients may be less symptomatic compared to patients 
recruited for previous PLD trials, this trial demonstrates that lanreotide decreases liver volume which 
is accepted as a surrogate marker for PLD severity. Third, not using a placebo is a limitation. 
However, our primary and secondary endpoints are objective measures (MRI volume), and endpoint 
analysis was performed after the trial finished blinded for patient identity, treatment allocation and 

















Our findings help to improve the understanding of the possible place of lanreotide treatment for PLD 
in the context of ADPKD. It provides evidence that suppression of the growth of cystic organs is part 
of the biological effect of somatostatin analogues. Therefore, in ADPKD patients with symptomatic 
PLD, long-term treatment with lanreotide should be considered. In previous PLD studies, 
somatostatin analogue treatment effect was not affected by the underlying inherited polycystic 
disorder.
6, 8
 This suggests that long-term somatostatin analogues treatment may not only be an 
option for ADPKD patients, but also for patients with the isolated form of polycystic liver disease 
(ADPLD). The benefit of somatostatin analogues with respect to intra-abdominal volume reduction 
should be weighed against a possible increased risk of hepatic cyst infections. This possible side 




In conclusion, this predefined sub-analysis of the DIPAK-1 trial shows that treatment with lanreotide 
for 120 weeks significantly decreases the growth rates of liver volume and combined liver- and 
kidney volume. Although lanreotide failed to protect ADPKD patients from renal function 
deterioration, we suggest that somatostatin analogue treatment can still have an important role in 
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Figure 1. Patient enrollment 
Abbreviations: TLV, total liver volume; BV, baseline visit; EOT, end of treatment; EET, early end of 
treatment; MRI, magnetic resonance imaging. 
Figure 2. Change in hTLV between baseline and end of treatment A) Estimated percent change (mean 
± 95% CI) in hTLV between baseline and end of treatment; B) percent change in hTLV, each bar 
represents 1 patient (dark bars – lanreotide, light bars – control group). All bars right from the 
scattered line represent decrease in hTLV, bars on the left represent increase in hTLV; C) subgroup 
analysis for the primary outcome. 
Figure 3. Percent change (mean ± 95% CI) in A) height adjusted liver volume at end of treatment 
(week 120) compared with baseline value; and B) height adjusted liver- and kidney volume at end of 






















Male sex – no. (%) 40 (43.0) 40 (48.9)   0.45 ¥ 
Age – yr 48.3 ± 6.2 48.0 ± 7.0 0.80 
Race – no. (%)     0.79 ¥ 
  White 91 (97.9) 80 (97.6)  
  Other 2 (2.2) 2 (2.4)  
Height – cm   1.78 ± 0.10  1.76 ± 0.10 0.45 
Weight – kg 86.0 ± 17.4 87.1 ± 20.0 0.69 
BMI – kg/m
2
 27.2 ± 4.3 27.9 ± 5.4 0.35 
Alkaline phosphatase – U/l  
Gamma-glutamyltransferase – U/l 
72.4 ± 23.2 
60.8 ± 51.2 
70.9 ±21.3 










 50.5 ± 11.4 51.2 ± 11.8 0.71 
CKD stages
†
 – no. (%)     0.71 
¥ 
  2 24 (25.8) 23 (28.1)  
  3a 33 (35.5) 31 (37.8)  
  3b 36 (38.7) 27 (32.9)  
  4 0 1 (1.2)  
Height adjusted total liver volume –  
ml/m 
1528 
(1250 – 2443) 
1376 
(1219 – 1687) 
0.04¤                             
  
Mild (<1600) – no. (%) 50 (53.8) 58 (70.7)  
Moderate (1600-3200) – no. (%) 30 (32.3) 19 (23.2)  
Severe (>3200) – no. (%) 13 (14.0) 5 (6.1)  
Height adjusted total kidney volume –  
ml/m 
1150 
(816 – 1778) 
1029 
(706 – 1920) 
0.53¤ 
 
Height adjusted total liver and kidney 
volume – ml/m 
3006 
(2460 – 4110) 
2694 
(2183 – 3683) 
0.04
¤ 
Plus–minus values are means ± SD and tested with Independent Samples T test . 
¤ 
Mann-Whitney U for 
non-parametric values (median (IQR)). 
¥
 Fisher’s Exact test 
Abbreviations: BMI, body mass index, GFR, glomerular filtration rate, CKD, chronic kidney disease  
¶
 To convert the values for creatinine to micromoles per liter, multiply by 88.4. 
† eGFR inclusion criterion for the trial was calculated with creaHnine at the screening visit and the 
MDRD equation, whereas by protocol amendment eGFR results for the trial are calculated with the 


















Table 2: Absolute and percentage change in (height adjusted) total liver volume (TLV)  
Baseline data are presented as median (interquartile range). Change at end of treatment and follow-up is 
presented as estimated marginal means with 95% CI (corrected for baseline volume). 
  
  Change 
 Baseline 
(week 0) 




Total Liver Volume 
Absolute (change in) TLV  
Control – ml 
N 
2389 (2168 to 3029) 
82 
89 (0 to 177) 
74 
79 (-28 to 187) 
70 
Lanreotide – ml  
N 
2781 (2272 to 4230) 
93 
-52 (-135 to 32) 
83 
-8 (-110 to 94) 
78 




-140 (-263 to -18) 
0.03 
-87 (-237 to 63) 
0.25 
Absolute (change in) hTLV 
Control – ml/m 
N 
1376 (1219 to 1687) 
82 
49 (-2.7 to 100.1) 
74 
40 (-22 to 102) 
70 
Lanreotide – ml/m  
N 
152 (1250 to 2443) 
93 
-30 (-78 to 19) 
83 
-4 (-63 to 54) 
78 




-79 (-150 to -7) 
0.03 
-45 (-131 to 412) 
0.31 
Percentage change in hTLV vs baseline 
Control - % 
N 
 3.92 (1.56 to 6.28) 
74 
2.71 (0.06 to 5.37) 
70 
Lanreotide - % 
N 
 -1.99 (-4.21 to 0.24) 
83 
-1.15 (-3.66 to 1.36) 
78 
Difference - % 
P-value 
 -5.91 (-9.18 to -2.63) 
<0.001 














Table 3: Absolute and percentage change in (height adjusted) total liver- and kidney volume (TLKV) 
Baseline data are presented as median (interquartile range). Change at end of treatment and follow-up is 
presented as estimated marginal means with 95% CI (corrected for baseline volume). 
 
  Change 
 Baseline 
(week 0) 




Combined Total Liver & Total Kidney Volume 
Absolute (change in) TLKV 
Control – ml 
N 
4632 (3906 to 6387) 
82 
518 (372 to 663) 
74 
532 (345 to 719) 
70 
Lanreotide – ml  
N 
5280 (4381 to 7214) 
93 
164 (27 to 301) 
83 
276 (99 to 453) 
78 




-353 (-554 to -152) 
0.001 
-256 (-515 to 4) 
0.05 
Absolute (change in) hTLKV 
Control – ml/m 
N 
2694 (2183 to 3683) 
82 
283 (13 to 169) 
74 
288 (182 to 394) 
70 
Lanreotide – ml/m  
N 
3006 (2460 to 4110) 
93 
91 (13 to 169) 
83 
154 (54 to 254) 
78 




-192 (-306 to -77) 
0.001 
-134 (-280 to 13) 
0.07 
Percentage change in hTLKV vs baseline 
Control - % 
N 
 9.39 (7.17 to 11.61) 
74 
9.32 (6.66 to 11.99) 
70 
Lanreotide - % 
N 
 2.21 (0.12 to 4.30) 
83 
3.89 (1.37 to 6.41) 
78 
Difference - % 
P-value 
 -7.18 (-10.25 to -4.12) 
<0.001 



































Included in the liver substudy (TLV>2000ml) 
175 patients 
    
 
 
 83 Completed study (BV & EOT/EET MRI available) 
      66 BV – EOT (120 weeks) 
      17 BV – EET; reason for EET:  
         10 side effects; 4 withdrawn b/o (suspected) liver cyst  
         infection; 1 cyst hemorrhage; 1 lack of clear benefit (renal  
         function decline); 1 work-up nephrectomy 
 
10 Discontinued study (EOT/EET MRI missing) 
      5 adverse events; 2 lost to follow-up; 1 withdrew consent;  
      1 died; 1 incomplete or not adequate MRI image 
 
74 Completed study (BV & EOT/EET MRI available) 
      73 BV-EOT (120 weeks) 
        1 BV-EET; reason for EET: 
           1 work-up kidney transplantation    
  8 Discontinued study (EOT/EET MRI missing) 
       4 Withdrew consent; 2 lost to follow-up; 





93 assigned to lanreotide group 
 
 
82 assigned to control group 
 
 
83 included in primary efficacy analysis 




74 included in primary efficacy analysis 







































Lanreotide Control Absolute treatment effect             Total change in hTLV (in %) P - value for 
N N Difference in change in hTLV (in %)    Lanreotide Control interaction
Overall 83 74 -1.99 (-4.21 to 0.24) 3.92 (1.56 to 6.28) <.001
Sex .27
   Male 39 35 0.12 (-3.09 to 3.33) 4,17 (0.68 to 7.66)
   Female 44 39 -3.91 (-6.98 to -0.80) 3.77 (0.55 to 6.98)
Age (year) .46
   ≤45 29 26 -1.14 (-4.90 to 2.68) 6.42 (2.45 to 10.40)
   >45 54 48 -2.45 (-5.19 to 0.29) 2.58 (-0.33 to 5.49)
hTLV at baseline (ml/m) .53
   Mild (<1600) 46 54 -3.23 (-6.42 to -0.05) 2.18 (-0.80 to 5.15)
   Moderate/severe (>1600) 37 20 0.09 (-3.96 to 4.13) 7.67 (2.91 to 12.44)
eGFR (ml/min/1,73m²) .07
   ≤45 30 23 -2.55 (-6.16 to 1.05) -1.07 (-5.22 to 3.09)
   >45 53 51 -1.61 (-4.34 to 1.12) 6.12 (3.35 to 8.89)
Alkaline phosphatase (U/L) .86
   ≤68 41 39 -0.27 (-3.45 to 2.90) 5,80 (2.50 to 9.11)
   >68 40 31 -3.84 (-7.14 to -0.54) 1.63 (-2.02 to 5.27)
Gamma glutamyltransferase (U/L) .66
   ≤41 38 44 -3.09 (-6.40 to 0.22) 3.61 (0.51 to 6.70)
   >41 45 30 -0.97 (-4.12 to 2.18) 4.27 (0.58 to 7.96)
      Favors lanreotide            Favors control















































































































Lanreotide Control Absolute treatment effect              Total change in hTLV (in %) P - value for 
N N Difference in change in hTLV (in %)    Lanreotide Control interaction
Overall 78 70 -1.15 (-3.66 to 1.36) 2.71 (0.06 to 5.37) .04
Sex .15
   Male 37 33 2.17 (-0.98 to 5.32) 3.94 (0.60 to 7.28)
   Female 41 37 -4.41 (-8.15 to -0.67) 1.92 (-2.03 to 5.86)
Age (year) .23
   ≤45 27 25 -1.12 (-5.63 to 3.40) 8,14 (3.43 to 12.84)
   >45 51 45 -1.56 (-4.42 to 1.30) 0,14 (-2.90 to 3.19)
hTLV at baseline (ml/m) .61
   Mild (<1600) 41 50 -1.77 (-4.99 to 1.46) 1.49 (-1.43 to 4.41)
   Moderate/severe (>1600) 37 20 -0.13 (-4.23 to 3.96) 5.16 (-0.43 to 10.75)
eGFR (ml/min/1,73m²) .21
   ≤45 29 20 -1.56 (-5.68 to 2.56) 0.01 (-4.98 to 5.00)
   >45 49 50 -1.01 (-4.18 to 2.16) 3.89 (0.75 to 7.04)
Alkaline phosphatase (U/L) .20
   ≤68 35 37 -1.20 (-4.86 to 2.46) 5.48 (1.92 to 9.04)
   >68 41 30 -1.23 (-4.85 to -2.39) -0.30 (-4.55 to 3.94)
Gamma glutamyltransferase (U/L) .69
   ≤41 35 40 -2.01 (-5.67 to 1.65) 2.47 (-0.95 to 5.89)
   >41 43 30 -0.56 (-4.10 to 2.97) 3.21 (-1.05 to 7.46)
      Favors lanreotide            Favors control













Lanreotide Control Absolute treatment effect                  Total change in hTLKV (in %) P - value for 
N N Difference in change in hTLKV (in %)    Lanreotide Control interaction
Overall 83 74 2.21 (0.12 to 4.30) 9.39 (7.17 to 11.61) .001
Sex .76
   Male 39 35 5.73 (2.81 to 8.65) 12.32 (9.27 to 15.38)
   Female 44 39 -0.82 (-3.54 to 1.90) 6.66 (3.75 to 9.57)
Age (year) .19
   ≤45 29 26 4.19 (0.70 to 7.68) 14.00 (10.38 to 17.62)
   >45 54 48 1.17 (-1.33 to 3.67) 6.87 (4.21 to 9.52)
hTLV at baseline (ml/m) .99
   Mild (<1600) 46 54 3.83 (1.03 to 6.64) 10.59 (7.96 to 13.22)
   Moderate/severe (>1600) 37 20 -0.07 (-3.35 to 3.22) 6.64 (2.39 to 10.89)
hTKV at baseline (ml/m) .94
   ≤1117 39 41 -0.05 (-3.07 to 2.96) 7.08 (4.00 to 10.15)
   >1117 44 33 4.50 (1.56 to 7.44) 11.88 (8.58 to 15.18)
hTLKV at baseline (ml/m) .16
   ≤2851 39 44 -4.88 (-8.51 to -1.24) 3.50 (-0.11 to 7.11)
   >2851 44 30 0.68 (-3.07 to 4.43) 4.39 (0.29 to 8.49)
eGFR (ml/min/1,73m²) .33
   ≤45 30 23 3.75 (0.25 to 7.25) 8.82 (4.86 to 12.78)
   >45 53 51 1.36 (-1.25 to 3.96) 9.63 (6.95 to 12.31)
Alkaline phosphatase (U/L) .51
   ≤68 41 39 3.53 (0.56 to 6.49) 11.31 (8.26 to 14.36)
   >68 40 31 1.03 (-1.99 to 4.05) 6.73 (3.31 to 10.15)
Gamma glutamyltransferase (U/L) .61
   ≤41 38 44 3.30 (0.20 to 6.40) 9.61 (6.71 to 12.50)
   >41 45 30 1.24 (-1.68 to 4.16) 9.15 (5.68 to 12.62)
              Favors lanreotide                 Favors control























Male sex – no. (%) 39 (47.0) 35 (47.3)  1.0
¥
 
Age – yr 48.2 ± 6.2 48.4 ± 6.9 0.89 
Race  – no. (%)    0.79
¥
 
    White 81 (97.6) 72 (97.3)  
    Other 2 (2.4) 2 (2.7)  
Height – cm     1.78 ± 0.10  1.76 ± 0.10 0.16 
Weight – kg 87.4 ± 17.4 86.1 ± 18.5 0.65 
BMI  – kg/m
2
 27.5 ± 4.4 27.8 ± 5.3 0.74 
Alkaline phosphatase – U/l  
Gamma-glutamyltransferase – U/l 
71.1 ± 22.0 
57.8 ± 45.8 
70.0 ±20.3 










 51.0 ± 11.3 51.7 ± 12.0 0.71 
CKD stages
†
 – no. (%)      0.68 
¥
 
   2 22 (26.5) 22 (29.7)  
   3a 31 (37.4) 29 (39.2)  
   3b 30 (36.1) 22 (29.7)  
   4 0 1 (1.35)  
Height corrected total liver volume –  
ml/m 
1514 
(1248 – 2161) 
1354 




                                                         
Mild (<1600) – no. (%) 46 (55.4) 54 (73.0)  
Moderate (1600-3200) – no. (%) 27 (32.5) 17 (23.0)  
Severe (>3200) – no. (%) 10 (12.1) 3 (4.1)  
Height corrected total kidney volume –  
ml/m 
1150 
 (813 – 1670) 
993 





Height corrected total liver and kidney volume 
– ml/m 
2942.0 
(2438 – 4105) 
2582.6 




Duration of follow-up 2.06 ±0.54 2.31 ± 0.06  <0.001 
Plus–minus values are means ± SD and tested with Independent Samples T test . 
¤ 
Mann-Whitney U for 
non-parametric values (median (IQR)). 
¥
 Fisher’s Exact test 
BMI body mass index, GFR glomerular filtration rate, CKD chronic kidney disease  
¶
 To convert the values for creatinine to micromoles per liter, multiply by 88.4. 
† eGFR inclusion criterion for the trial was calculated with creaFnine at the screening visit and the 
MDRD equation, whereas by protocol amendment eGFR results for the trial are calculated with the 















Supplementary Table 2: Sensitivity analysis for patients lost to follow-up in the Lanreotide Group (n=93) 
 
Characteristic In analysis 
(N=83) 
Lost to FU 
(N=10) 
P value 
Male sex – no. (%) 39 (47.0) 1 (10.0) 0.04 
¥
 
Age – yr 48.2 ± 6.2 48.4 ± 6.7 0.94 
Race  – no. (%)   1.0 
¥
 
    White 81 (97.6) 10 (100)  
    Other 2 (2.4) 0 (0)  
Height – cm     1.78 ± 0.10  1.72 ± 0.09 0.07 
Weight – kg 87.4 ± 17.4 74.0 ± 12.1 0.02 
BMI  – kg/m
2
 27.5 ± 4.4 24.6 ± 2.7 <0.05 
Alkaline phosphatase – U/l  
Gamma-glutamyltransferase – U/l 
71.1 ± 22.0 
57.8 ± 45.8 
83.1 ±30.3 










 51.0 ± 11.3 46.9 ± 12.1 0.29 
CKD stages
†
 – no. (%)   0.37 
¥
 
   2 22 (26.5) 2 (20.0)  
   3a 31 (37.4) 2 (20.0)  
   3b 30 (36.1) 6 (60.0)  
   4 0 0 (0)  
Height corrected total liver volume –  
ml/m 
1514 
(1248 – 2161) 
2429 




                                                     
Mild (<1600) – no. (%) 46 (55.4) 4 (40.0)  
Moderate (1600-3200) – no. (%) 27 (32.5) 3 (40.0)  
Severe (>3200) – no. (%) 10 (12.1) 3 (30.0)  
Height corrected total kidney volume –  
ml/m 
1150 
 (813 – 1670) 
1314 





Height corrected total liver and kidney volume 
– ml/m 
2942.0 
(2438 – 4105) 
3264 





Plus–minus values are means ± SD and tested with Independent Samples T test . 
¤ 
Mann-Whitney U 
for non-parametric values (median (IQR)). 
¥
 Fisher’s Exact test 
 BMI body mass index, GFR glomerular filtration rate, CKD chronic kidney disease  
¶
 To convert the values for creatinine to micromoles per liter, multiply by 88.4. 
† eGFR inclusion criterion for the trial was calculated with creaFnine at the screening visit and the 
MDRD equation, whereas by protocol amendment eGFR results for the trial are calculated with the 
















Supplementary Table 3: Sensitivity analysis for patients lost to follow-up in the control group (n=82) 
 
Characteristic In analyses 
(N=74) 
Lost to FU 
(N=8) 
P value 
Male sex – no. (%) 35 (47.3) 5 (62.5) 0.48 
¥
 
Age – yr 48.4 ± 6.9 44.4 ± 7.4 0.12 
Race  – no. (%)   1.0 
¥
 
    White 72 (97.3) 8 (100)  
    Other 2 (2.7) 0 (0)  
Height – cm     1.76 ± 0.10 1.81 ± 0.10 0.21 
Weight – kg 86.1 ± 18.5 96.5 ± 30.9 0.16 
BMI  – kg/m
2
 27.8 ± 5.3 29.1 ± 6.9 0.5 
Alkaline phosphatase – U/l  
Gamma-glutamyltransferase – U/l 
70.0 ±20.3 
47.7 ± 36.8 
78.3 ±29.2 
110.3 ± 112.8 
0.30 
<0.001                                                         
Serum creatinine
¶ 





 51.7 ± 12.0 46.7 ± 10.0 0.26 
CKD stages
†
 – no. (%)   0.30 
¥
 
   2 22 (29.7) 1 (12.5)  
   3a 29 (39.2) 2 (25.0)  
   3b 22 (29.7) 5 (62.5)  
   4 1 (1.35) 0 (0)  
Height corrected total liver volume –  
ml/m 
1354 
(1218 – 1627) 
1842 




                                                         
Mild (<1600) – no. (%) 54 (73.0) 4 (50.0)  
Moderate (1600-3200) – no. (%) 17 (23.0) 2 (25.0)  
Severe (>3200) – no. (%) 3 (4.1) 2 (25.0)  
Height corrected total kidney volume –  
ml/m 
993 
(682 – 2057) 
1304 





Height corrected total liver and kidney volume 
– ml/m 
2582.6 
(2178 – 3605) 
3589 





Plus–minus values are means ± SD and tested with Independent Samples T test . 
¤ 
Mann-Whitney U 
for non-parametric values (median (IQR)). 
¥
 Fisher’s Exact test 
 BMI body mass index, GFR glomerular filtration rate, CK  chronic kidney disease  
¶
 To convert the values for creatinine to micromoles per liter, multiply by 88.4. 
† eGFR inclusion criterion for the trial was calculated with creatinine at the screening visit and the 
MDRD equation, whereas by protocol amendment eGFR results for the trial are calculated with the 















Supplementary table 4: Annualized percentage change in height adjusted total liver volume and 


















Change at end of treatment and follow-up is presented as estimated marginal means with 95% CI 
(corrected for baseline volume). 
  
 Change 




Percentage change per year in hTLV vs baseline 
Control - %/year 
N 
1.65 (0.08 to 3.23) 
74 
1.02 (-0.38 to 2.41) 
70 
Lanreotide - %/year 
N 
-1.72(-3.21 to -0.23) 
83 
-0.73 (-2.05 to 0.59) 
78 
Difference - %/year 
P-value 
-3.37 (-5.56 to -1.19) 
0.003 
-1.75 (-3.68 to 0.19) 
0.08 
  Percentage change per year in hTLKV vs baseline 
Control - %/year 
N 
4.06 (2.59 to 5.53) 
74 
3.63 (2.33 to 4.94) 
70 
Lanreotide - %/year 
N 
0.36 (-1.03 to 1.74) 
83 
1.32 (0.09 to 2.56) 
78 
Difference - %/year 
P-value 
-3.70 (-5.74 to -1.67) 
<0.001 














Supplementary Table 5: Absolute and percentage change in (height adjusted) total kidney volume (TKV) 
Baseline data are presented as median (interquartile range). Change at end of treatment and follow-up is 
presented as estimated marginal means with 95% CI (corrected for baseline volume). 
  
  Change 
 Baseline 
(week 0) 




Total Kidney Volume 
Absolute (change in) TKV  
Control – ml 
N 
1874 (1253 to 3530) 
82 
392 (306 to 479) 
74 
420 (300 to 539) 
70 
Lanreotide – ml  
N 
2054 (1452 – 3012) 
93 
246 (165 to 328) 
84 
310 (197 to 422) 
79 




-146 (-265 to -27) 
0.02 
-110 (-275 to 55) 
0.19 
Absolute (change in) hTKV 
Control – ml/m 
N 
1029 (706 to 1920) 
82 
217 (169 to 265) 
74 
232 (167 to 298) 
70 
Lanreotide – ml/m  
N 
1150 (81 to 1778) 
93 
135 (91 to 180) 
84 
170 (109 to 232) 
79 




-82 (-147 to -16) 
0.02 
-62 (-152 to 28) 
0.17 
Percentage change in hTKV vs baseline 
Control - % 
N 
 15.65 (12.74 to 18.55) 
74 
17.12 (12.90 to 21.34) 
70 
Lanreotide - % 
N 
 7.62 (4.89 to 10.34) 
84 
10.45 (6.48 to 14.42) 
79 
Difference - % 
P-value 
 -8.03 (-12.01 to -4.05)  
<0.001 














Supplementary Table 6: Absolute and percentage change versus baseline in (height adjusted) total liver 
volume (TLV), total kidney volume (TKV) and total liver and kidney volume (TLKV), excluding the outlier with 
very rapid disease progression.   




  Change 




Total Liver Volume 
Absolute change in TLV  
Difference - ml 
P-value 
 
-142 (-263 to -21) 
0.02 
-89 (-231 to 53) 
0.22 
Absolute change in hTLV 
Difference – ml/m 
P-value 
 
-80 (-151 to -10) 
0.03 
-48 (-130 to 34) 
0.25 
Percentage change in hTLV  
Difference - % 
P-value 
 -5.94 (-9.22 to -2.67) 
<0.001 
-3.93 (-7.60 to -0.26)  
0.04 
Total Kidney Volume 
Absolute change in TKV 
Difference - ml 
P-value 
 -165 (-278 to -52) 
0.004 
-154 (-290 to -18) 
0.03 
Absolute change in hTKV 
Difference – ml/m 
P-value 
 -92 (-154 to -30) 
0.004 
-86 (-161 to -11) 
0.03 
Percentage change in hTKV  
Difference - % 
P-value 
 -8.84 (-12.46 to -5.22)  
<0.001 
-8.51 (-12.84 to -4.18) 
<0.001 
Combined Total Liver & Total Kidney Volume 
Absolute change in TLKV 
Difference - ml 
P-value 
 -364 (-560 to -167) 
<0.001 
-282 (-508 to -56) 
0.02 
Absolute change in hTLKV 
Difference – ml/m 
P-value 
 -198 (-310 to -86) 
0.001 
-151 (-279 to -22) 
0.02 
Percentage change in hTLKV  
Difference - % 
P-value 
 -7.29 (-10.34 – -4.24) 
<0.001 














Supplementary Table 7.  Most common Serious Adverse Events. Listed are all serious adverse events with an 















 No. of patients with event (%) 
Serious adverse events   
Any serious adverse event 28 (30.1%) 10 (12.2%) 
Serious adverse event leading to withdrawal   4 (4.3%) 1 (1.2%) 
Specific serious adverse events possibly related to 
lanreotide 
  
- Hepatic cyst infection 6 (6.5%) 0 
- Renal cyst infection 2 (2.2%) 2 (2.4%) 
- Pyelonephritis 1 (1.1%) 1 (1.2%) 
- Epigastric pain 1 (1.1%) 0 
- Fever 1 (1.1%) 0 
- Urinary tract infection 1 (1.1%) 0 
- Cholelithiasis 1 (1.1%) 0 
Adverse events were collected by spontaneous report. A full list of adverse events of the complete DIPAK-1 study 
have been published elsewhere.14  
* Adverse events were categorized according to the preferred terms of the Medical Dictionary for Regulatory 
Activities (MedDRA). 
#















Supplementary Table 8: Summary of studies performed with somatostatin analogues in patients with polycystic kidney disease, and differences in characteristics with the 
present study.  
Abbreviations: im, intramuscular; sc, subcutaneous; wks, weeks; N, number of patients; ADPKD, autosomal dominant polycystic kidney disease; ADPLD, autosomal 
dominant polycystic liver disease; PLD, polycystic liver disease; RCT, randomized controlled trial; GFR, glomerular filtration rate; SA, somatostatin analogues; Pla, placebo; 




 Mean with 95%CI or standard deviation , 
£ 




Somatostatin analogue Trial design Duration 
 
Nr. of patients Nr. of males 
in SA group 




























Pla: +1.6 vs Lan: -2.9% 
P<0.01 
Hogan et al,  
2010 
Octreotide 














70 Pla: +0.92 vs Oct: -4.95% 
P<0.05 
Caroli et al, 
2010 
Octreotide 
40 mg im every 4 wks 
Cross-over 6 months N=12 
ADPKD 
 




57 Pla: +1.0 vs Oct: -4.9% 
P<0.05 
Pisani et al, 
2016 
Octreotide 




3 years N=27  
ADPKD 
 




96 Pla: +6.1 vs Oct: -7.8% 
P<0.05 
 

























Control: +3.92% vs  
Lan: -1.99% 
P<0.001 




























Figure legends (supplementary figures) 
Supplementary Figure 1. Subgroup analysis for the change in hTLV between baseline and post-treatment (week 
132) 
 
Supplementary Figure 2. Subgroup analysis for the change in hTLKV between baseline and end of treatment 
(week 120) 
 
 
 
